Overview
- Brazil’s health regulator approved Wegovy to lower the risk of heart attack and stroke in adults with established cardiovascular disease who also have obesity or overweight.
- Ozempic’s label now includes treatment for people with type 2 diabetes and chronic kidney disease, with studies showing slower kidney decline and fewer cardiovascular deaths when added to standard care.
- Novo Nordisk filed for Anvisa approval of a 25 mg oral Wegovy on January 30 after a late‑December FDA clearance, reporting average weight loss around 16.6% to 17% and a safety profile similar to the injectable with mostly mild gastrointestinal effects.
- A Lancet‑published analysis from the SELECT trial found semaglutide’s cardiovascular protection was not fully explained by the amount of weight lost.
- Novo Nordisk reported phase 3 REIMAGINE results showing its combination injection CagriSema produced greater weight loss than Wegovy in trials, including 14.2% versus 10.2% after 68 weeks in adults with type 2 diabetes.